Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)
Sponsor: ILiAD Biotechnologies
Listed as NCT05116241, this PHASE2 trial focuses on Bordetella Pertussis, Whooping Cough and remains completed. Sponsored by ILiAD Biotechnologies, it has been updated 12 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Feb 2025 — Dec 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ILiAD Biotechnologies
For direct contact, visit the study record on ClinicalTrials.gov .